Zacks.com on MSN

Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?

Cartesian Therapeutics, Inc. (RNAC) shares ended the last trading session 10.3% higher at $7.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet

Cartesian Therapeutics' lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b. Find ...
FierceBiotech

Cartesian claims phase 2b autoimmune CAR-T win after changing endpoint

Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and ...
The Caledonian-Record

Factorial Names Dr. Dieter Zetsche to Board of Directors, Bringing World-Class Leadership to Its Commercial Scale and Public Market Journey

Factorial Inc. (“Factorial”), a leader in solid-state battery technology, today announced that, upon the closing of the ...
Yahoo Finance

Factorial and Cartesian Growth Corporation III (Nasdaq: CGCT) Announce Business Combination Agreement to Accelerate Commercialization of Solid-State Battery Technology

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...